{"filings":[{"id":2384958,"accession_number":"0001193125-26-359418","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2026-08-20T21:28:20+00:00","items":["1.01","9.01"],"status":"ready","headline":"Amylyx prices $471.7M equity offering to fund avexitide launch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["14,090,000 shares at $35.50/share; 30-day option for 2,113,500 more.","Net proceeds ~$471.7M (~$542.5M if option fully exercised).","Proceeds to fund potential U.S. launch of avexitide, R&D, working capital.","Offering expected to close Aug 21, 2026; underwriters: Leerink, Morgan Stanley, Guggenheim, LifeSci."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2310836,"accession_number":"0001193125-26-354793","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2026-08-18T13:03:53+00:00","items":["8.01","9.01"],"status":"ready","headline":"Amylyx announces positive topline Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Positive topline results announced Aug 18, 2026 from LUCIDITY Phase 3 trial of avexitide in post-bariatric hypoglycemia (PBH).","Trial enrolled participants with PBH following Roux-en-Y gastric bypass surgery; no efficacy numbers disclosed in filing text.","Investor conference call and slide deck (Exhibit 99.1) held same day; detailed endpoint data not included in available excerpt.","Avexitide is Amylyx's (AMLX) candidate for PBH; positive readout could support registration pathway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2309796,"accession_number":"0001193125-26-354716","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2026-08-18T11:09:58+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Amylyx reports positive Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LUCIDITY met primary endpoint: 55% reduction in composite Level 2/3 hypoglycemic events vs placebo (p=0.000003).","All secondary endpoints met: reductions in SMBG-measured Level 2, CGM-measured Level 2, and adjudicated Level 3 events.","Trial enrolled 78 adults with PBH post-RYGB; randomized 3:2 to 90 mg avexitide SC daily or placebo.","NDA submission to FDA planned by end of 2026; avexitide has Breakthrough Therapy and Orphan Drug designations.","Avexitide well-tolerated; no serious AEs related to treatment; common AEs: diarrhea, injection site erythema, bruising."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-08-18","daily_digest_url":"/daily/2026-08-18","daily_digest_rank":10},{"id":2088089,"accession_number":"0001193125-26-336670","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2026-08-06T11:02:19+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx Q2 net loss $43.4M; Phase 3 PBH topline data expected late Aug/early Sep 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $43.4M ($0.39 per share) vs $41.4M ($0.46 per share) in Q2 2025.","Cash, equivalents, and short-term investments $250.8M at June 30, 2026; runway into 2028.","R&D expenses $23.8M (down from $27.2M); SG&A $21.9M (up from $15.6M) on legal and commercial investment.","Last participant completed final visit in Phase 3 LUCIDITY trial of avexitide in PBH; topline data on track for late Aug/early Sep 2026.","Expanded Access Program for avexitide initiated; second research collaboration with Gubra A/S announced."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":860917,"accession_number":"0001193125-26-257390","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2026-06-04T20:06:58+00:00","items":["5.07"],"status":"ready","headline":"Amylyx stockholders elect directors, ratify auditor, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected George Mclean Milne Jr., Ph.D. (76.9M for, 14.1M withheld) and Paul Fonteyne (86.3M for, 4.8M withheld) as Class II directors.","Ratified Deloitte & Touche as independent auditor for FY 2026: 102.0M for, 34.5K against, 5.6K abstain.","Approved non-binding advisory vote on named executive officer compensation: 77.5M for, 13.5M against, 21.1K abstain.","No other matters were voted on at the June 4, 2026 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94483,"accession_number":"0001193125-26-210286","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx Q1 net loss $41.3M; Phase 3 avexitide topline data in Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $41.3M ($0.37 per share) vs $35.9M ($0.42) in Q1 2025; cash used in operations.","Cash $279.8M at March 31, 2026, down from $317.0M; runway expected into 2028.","R&D expense rose to $27.6M, driven by avexitide trial costs and $4M Gubra milestone.","Phase 3 LUCIDITY for avexitide (PBH) enrollment complete; topline data in Q3 2026.","Early biomarker data from LUMINA Phase 1 for AMX0114 (ALS) expected at ENCALS June 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106892,"accession_number":"0001193125-26-120691","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Amylyx updates corporate presentation: Phase 3 LUCIDITY enrollment complete, Phase 2 PREVENT analysis added","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed enrollment in Phase 3 LUCIDITY trial.","Added exploratory analysis of Phase 2 PREVENT study from ENDO 2025.","Completed enrollment for Cohort 2 of Phase 1 LUMINA trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106891,"accession_number":"0001193125-26-086629","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx reports FY2025 net loss of $144.7M; avexitide Phase 3 enrollment complete, topline data Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2025: $144.7M ($1.53/share) vs $301.7M ($4.43/share) in FY2024.","Phase 3 LUCIDITY trial of avexitide in PBH enrollment complete; topline data expected Q3 2026, potential launch 2027.","Cash, equivalents, and short-term investments $317.0M at Dec 31, 2025; cash runway into 2028.","R&D expenses decreased to $90.4M from $104.1M due to lower AMX0035 spending, offset by increased avexitide costs.","Selected AMX0318 (GLP-1 receptor antagonist) as development candidate for PBH; IND filing targeted 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106890,"accession_number":"0001193125-26-006991","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Amylyx selects GLP-1 antagonist AMX0318 as development candidate for post-bariatric hypoglycemia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AMX0318 is a long-acting GLP-1 receptor antagonist for post-bariatric hypoglycemia and other rare diseases.","Candidate identified through research collaboration with Gubra; Gubra eligible for >$50M in development and commercial milestones.","Handover of candidate triggers $4M milestone payment to Gubra; mid-single digit royalties on worldwide net sales.","Amylyx expects to initiate IND-enabling studies and file an IND for AMX0318, though no specific timeline was provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123213,"accession_number":"0001193125-25-268043","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx Q3 net loss narrows to $34.4M; cash $344M after $191M offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $34.4M ($0.37/sh) vs $72.7M ($1.07/sh) in Q3 2024; R&D $19.9M, SG&A $16.2M.","Cash and securities $344M at Sept 30, up from $180.8M at June 30; cash runway into 2028.","Phase 3 LUCIDITY trial of avexitide recruitment completion expected Q1 2026; topline data Q3 2026.","Phase 1 LUMINA trial of AMX0114 in ALS fully enrolled cohort 1; early data at Dec symposium.","Plan to initiate Phase 3 trial of AMX0035 in Wolfram syndrome H2 2026 pending FDA alignment."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139886,"accession_number":"0001193125-25-200159","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Amylyx launches $164M common stock offering at $10.00 per share to fund avexitide launch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 17.5M shares (2.625M option) at $10.00/share; net proceeds ~$164M, up to ~$188.7M.","Proceeds to advance avexitide commercial readiness, R&D, working capital, and general corporate purposes.","Underwriting led by Leerink Partners and Guggenheim Securities; expected closing September 11, 2025.","Underwriters granted 30-day option to purchase up to 2.625M additional shares at offering price less discounts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139885,"accession_number":"0001193125-25-189109","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Amylyx discontinues AMX0035 program for PSP after Phase 2b miss","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AMX0035 failed to show differences vs placebo on primary or secondary outcomes at Week 24.","Company will discontinue Phase 2b trial and open-label extension; will not proceed to Phase 3.","Safety data consistent with prior AMX0035 studies.","ORION program for progressive supranuclear palsy (PSP) is discontinued entirely."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139884,"accession_number":"0000950170-25-104546","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx Q2 net loss narrows to $41.4M; cash $180.8M; pipeline milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $41.4M ($0.46 per share) vs $72.7M ($1.07) in Q2 2024; lower SG&A and R&D spend in ALS.","Cash, equivalents, and marketable securities $180.8M at June 30, 2025; runway expected through end of 2026.","Pivotal Phase 3 LUCIDITY trial of avexitide in PBH fully enrolled in 2025; topline data H1 2026; potential launch 2027.","Phase 2b ORION trial (AMX0035) in PSP unblinded analysis expected Q3 2025 to inform Phase 3 go/no-go.","FDA Fast Track granted for AMX0114 (antisense oligo) in ALS; early LUMINA Phase 1 data expected 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157480,"accession_number":"0001193125-25-135860","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Amylyx shareholders elect three Class I directors; ratify Deloitte; approve say-on-pay proposal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Karen Firestone, Justin Klee, and Bernhardt Zeiher elected as Class I directors for term ending 2028. Firestone and Zeiher each had ~21.3M votes withheld; Klee had 1.5M.","Ratification of Deloitte & Touche as auditor for FY 2025 passed with 72.5M for vs 34.7K against.","Non-binding advisory vote on executive compensation passed with 33.1M for, 24.1M against, and 2.0M abstentions.","Total shares voted: ~72.5M on auditor proposal; broker non-votes of 15.4M on director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157479,"accession_number":"0000950170-25-066355","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx Q1 net loss $35.9M, cash $204.1M; avexitide Phase 3 underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $35.9M ($0.42/share), down from $118.8M ($1.75/share) YoY on lower R&D and SG&A costs.","Cash, equivalents, and marketable securities $204.1M; cash runway expected through end of 2026.","Phase 3 LUCIDITY trial of avexitide in PBH dosed first patient; enrollment complete 2025, topline data H1 2026.","Phase 1 LUMINA trial of AMX0114 (ASO for ALS) dosed first patient; early cohort data expected in 2025.","Closed $65.5M public offering of 19.7M shares in Jan 2025; Phase 2b ORION (PSP) data expected Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175862,"accession_number":"0000950170-25-031303","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx reports Q4 net loss of $37.5M, cash runway extended through 2026 after $65.5M raise","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q4 2024 was $37.5M ($0.55 per share); FY2024 net loss of $301.7M ($4.43 per share).","Cash, equivalents & short-term investments were $176.5M at Dec 31, 2024; plus $65.5M raised in Jan 2025.","Phase 3 LUCIDITY trial of avexitide in PBH recruiting; topline data expected first half 2026.","Appointed Dan Monahan as Chief Commercial Officer to lead commercialization strategy.","R&D expenses fell to $22.9M in Q4 2024 from $44.9M in Q4 2023; SG&A fell to $17.1M from $52.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175861,"accession_number":"0001193125-25-004547","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Amylyx prices 17.1M-share public offering at $3.50/sh for ~$56.9M net proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 17,142,857 common shares at $3.50 per share, with 30-day option for up to 2,571,428 additional shares.","Net proceeds expected to be ~$56.9 million ($65.5 million if over-allotment exercised in full).","Closing expected January 13, 2025; proceeds to fund commercialization prep, pipeline, working capital.","Underwriting agreement includes customary representations, warranties, and market standoff provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192764,"accession_number":"0001193125-24-286212","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Amylyx and Gubra collaborate on GLP-1 antagonist; milestones up to >$50M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration with Gubra to develop a novel long-acting GLP-1 receptor antagonist; Amylyx to make small upfront and research payments (not material).","Gubra eligible for >$50M in success-based development and commercialization milestones plus mid-single digit royalties.","Amylyx expects cash runway into 2026; upfront and research payments not material to the company.","Screening to identify lead development candidate for IND-enabling studies; Amylyx has option to lead development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192763,"accession_number":"0000950170-24-122779","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx reports Q3 net loss of $72.7M; cash $234.4M; pipeline updates on AMX0035, avexitide, AMX0114","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $72.7M ($1.07 loss per share) vs net income of $20.9M in Q3 2023; acquired IPR&D expense of $36.2M for avexitide.","Cash, cash equivalents and marketable securities of $234.4M as of Sept. 30, 2024, down from $309.8M at June 30, 2024; runway into 2026.","Positive Phase 2 HELIOS data for AMX0035 in Wolfram syndrome: met primary endpoint (C-peptide improvement), with stabilization across secondary measures.","Avexitide Phase 3 program in post-bariatric hypoglycemia on track to initiate in Q1 2025; topline data expected in 2026.","FDA placed clinical hold on AMX0114 ALS trial, requesting lower starting dose; Amylyx plans to start LUMINA trial in Canada by end of 2024/early 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":88036000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192762,"accession_number":"0001193125-24-238572","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"HELIOS Phase 2: AMX0035 improves C-peptide AUC by +3.8 min*ng/mL at Week 24 in Wolfram syndrome","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint: C-peptide AUC improved at Week 24 (ITT +3.8 min*ng/mL; Per Protocol +20.2) and sustained through Week 48 (+36.7).","Glycemic control: HbA1c decreased (-0.09% at Week 24 to -0.35% at Week 36); time in target glucose range increased (+5.2% to +12.3%).","All 12 participants showed stability/improvement on CGIC and PGIC; no serious AEs related to AMX0035; diarrhea most common.","FDA and EU granted Orphan Drug Designation; company plans to meet FDA to discuss Phase 3, update in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209202,"accession_number":"0000950170-24-093304","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx Q2 net loss $72.7M; revenue negative after RELYVRIO withdrawal; avexitide acquisition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $72.7M ($1.07/share) vs net income $22.1M ($0.31) a year ago; revenue negative $(1.0)M after RELYVRIO/ALBRIOZA withdrawal.","Cash $309.8M at June 30, down from $373.3M at March 31; runway into 2026.","Acquired avexitide (GLP-1 antagonist) with FDA Breakthrough Therapy; PBH Phase 3 plan Q1 2025.","Restructuring $22.9M largely severance; headcount reduced after PHOENIX failure and product discontinuation.","R&D down to $23.3M, SG&A to $21.6M; cost cuts and pipeline shift from RELYVRIO."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":87620000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209201,"accession_number":"0001193125-24-177000","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["2.01"],"status":"ready","headline":"Amylyx completes acquisition of Avexitide from Eiger for $35.1M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired Avexitide from Eiger BioPharmaceuticals for $35.1 million plus cure costs and assumed liabilities.","Sale approved by U.S. Bankruptcy Court for Northern District of Texas on June 26, 2024; closed July 9, 2024.","Amylyx will handle development, manufacture, and commercialization of Avexitide post-closing.","Transaction follows Asset Purchase Agreement dated June 21, 2024, as previously disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227125,"accession_number":"0000950170-24-076339","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Amylyx acquires Avexitide from bankrupt Eiger BioPharma for $35.1M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquires substantially all assets for Avexitide, a GLP-1 receptor antagonist, from Eiger BioPharmaceuticals.","Total purchase price $35.1M plus determined cure costs capped at $277,703.63.","Transaction subject to Bankruptcy Court approval; Eiger filed Chapter 11 on April 1, 2024.","Deal includes assigned contracts and regulatory filings; closing expected after court order.","Amylyx deposits $1.755M into escrow as deposit per approved bid procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227124,"accession_number":"0001193125-24-156050","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Amylyx shareholders elect Cohen, Quimi as directors; ratify Deloitte","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Joshua Cohen and Daphne Quimi elected as Class III directors with ~32.6M and ~32.5M votes for, respectively.","Deloitte & Touche LLP ratified as independent auditor for FY2024 with 52,023,591 votes for, 162,947 against.","Non-binding advisory vote on NEO compensation approved: 41,211,831 for, 2,708,178 against, 38,594 abstain.","Shareholders chose 'One Year' as preferred frequency for future say-on-pay votes (38,275,989 for one year).","Broker non-votes of 8,341,537 on director elections and executive compensation proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227123,"accession_number":"0000950170-24-056254","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx Q1 net loss $118.8M; discontinues RELYVRIO/ALBRIOZA; inventory write-down $110.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $118.8M ($1.75 diluted per share) vs. net income of $1.6M in Q1 2023.","Net product revenue $88.6M, up 24% YoY; includes $110.5M non-cash inventory write-down due to product withdrawal.","Voluntarily discontinuing RELYVRIO/ALBRIOZA for ALS; existing patients transitioned to free drug program.","Cash $373.3M, expected runway into 2026; interim HELIOS Wolfram data show improvement; topline from 12 patients expected fall 2024.","Phase 3 ORION PSP trial data expected mid-2025; IND and clinical trial of AMX0114 in ALS planned for H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":88643000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227122,"accession_number":"0001193125-24-091463","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Interim Phase 2 data for AMX0035 shows clinically meaningful effects in Wolfram syndrome (n=8)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["C-peptide AUC increased +15.6 ng*min/mL at Week 24; 7 of 8 participants had shorter time to peak C-peptide.","HbA1c reduced by 0.26% on average; 6 of 8 improved; time in target glucose range improved by +7.1%.","Visual acuity improved in 5 of 8 participants; one participant changed from legally blind to sighted.","All 8 participants showed disease stability or improvement per CGIC and PGIC; no serious AEs related to AMX0035."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227121,"accession_number":"0001193125-24-086609","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-04-04T23:59:59+00:00","items":["2.05","7.01","8.01","9.01"],"status":"ready","headline":"Amylyx pulls RELYVRIO from market after Phase 3 miss, cuts 70% of staff","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Voluntarily discontinues RELYVRIO/ALBRIOZA in U.S. and Canada; no new patients after today.","Workforce reduced ~70%; expects $19M in severance charges; cash runway extended into 2026.","Current patients may transition to free drug program; PHOENIX Open Label Extension ongoing.","Interim data from Phase 2 HELIOS (AMX0035 in Wolfram) due April 2024; webcast Apr 10.","AMX0114 for ALS expects to start clinical trial in 2H 2024; ORION PSP interim analysis mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246019,"accession_number":"0001193125-24-067471","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Amylyx appoints Dr. Bernhardt Zeiher to board, fills Class I director vacancy","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed March 14, 2024 as Class I director; term expires at 2025 annual meeting.","Also named to Nominating and Corporate Governance Committee, replacing Paul Fonteyne.","Zeiher was Chief Medical Officer at Astellas Pharma from 2018-2022; joined Entrada Therapeutics board in 2023.","Receives initial option grant (lesser of $570K value or 50K shares); 1/3 vests at one year, remainder over two years.","Annual retainer of $45,000 plus $5,000 for Nominating Committee service; eligible for annual option grants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246018,"accession_number":"0001193125-24-062878","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Amylyx Phase 3 ALS trial misses primary endpoint; may withdraw RELYVRIO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PHOENIX trial: no significant difference on ALSFRS-R at Week 48 (p=0.667); secondary endpoints also missed.","Company may voluntarily withdraw RELYVRIO/ALBRIOZA from market; will decide within 8 weeks after regulatory discussions.","Promotion paused immediately; drug and patient support remain available for now.","Study enrolled 664 adults; safety profile consistent, no new signals.","Phase 3 ORION in PSP and Phase 2 HELIOS in Wolfram syndrome continue as planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246017,"accession_number":"0000950170-24-018409","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx reports FY 2023 net income $49.3M vs loss; product revenue $380.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2023 net product revenue $380.8M; Q4 revenue $108.4M vs $102.7M in Q3 2023.","Net income of $49.3M (diluted EPS $0.70) for 2023 vs net loss of $198.4M ($3.39 loss per share) in 2022.","Cash, cash equivalents and short-term investments of $371.4M at Dec 31, 2023 vs $355.0M at Sep 30, 2023.","Phase 3 PHOENIX trial topline data expected Q1/Q2 2024; Phase 3 ORION trial dosed first patient Dec 2023, data 2025-2026.","Appointed Camille Bedrosian CMO, Linda Arsenault CHRO, Dan Monahan GM & Head of U.S. Commercial in late 2023/early 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":380786000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263473,"accession_number":"0001193125-23-290302","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2023-12-07T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Amylyx CCO Margaret Olinger to depart Dec 31, 2023; search underway","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Margaret Olinger, Chief Commercial Officer, will leave Amylyx effective end of day Dec 31, 2023.","Company has initiated a search for a new Chief Commercial Officer.","Olinger's departure is not related to any disagreement with Amylyx regarding operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263472,"accession_number":"0000950170-23-061505","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx reports Q3 product revenue $102.7M, net income $20.9M, PHOENIX topline Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $102.7M (Q3) vs $98.2M (Q2 2023) and $0.3M (Q3 2022).","Net income $20.9M ($0.30 diluted EPS) compared to net loss $53.8M in Q3 2022.","Cash, equivalents and short-term investments $355.0M at Sept 30, 2023.","Post hoc analysis: median overall survival 10.4 months longer with AMX0035 vs historical control.","CHMP reaffirmed negative EU opinion; final decision end 2023. PHOENIX Phase 3 topline expected Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":272337000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263471,"accession_number":"0001193125-23-256178","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2023-10-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CHMP confirms negative opinion on Amylyx's AMX0035 for ALS in EU","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CHMP confirmed its initial negative opinion on Marketing Authorisation Application for AMX0035 (ALBRIOZA) for ALS.","Formal re-examination procedure concluded, upholding June 2023 initial negative opinion.","Decision applies to European Union marketing authorization for AMX0035."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280693,"accession_number":"0000950170-23-041274","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx Q2 product revenue $98.2M, net income $22.1M; CHMP re-examining MAA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $98.2M in Q2 2023 (up from $71.4M in Q1); net income $22.1M ($0.31 diluted EPS).","Cash, equivalents and short-term investments $357.3M at June 30, 2023.","Phase 3 ORION trial of AMX0035 for PSP to start by year-end; ~600 participants planned.","CHMP re-examining negative opinion on AMX0035 MAA for ALS; final opinion expected fall 2023.","Five Canadian provinces now reimburse ALBRIOZA; broad public coverage expected by end of August."],"consensus_eps_estimate":null,"consensus_eps_actual":0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":169644000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280692,"accession_number":"0001193125-23-194655","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Amylyx announces conference call on AMX0035 Phase 3 PSP trial; no new data","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Hosted investor call on July 26, 2023 to discuss PSP and Orion Phase 3 trial of AMX0035.","No clinical results or data disclosed; only trial design and scientific rationale overview.","Presenters included co-CEOs, clinical development head, and external investigator Prof. Höglinger.","Attached slides outline rationale and design, not outcomes or milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299320,"accession_number":"0001193125-23-173965","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Amylyx receives CHMP negative opinion for AMX0035 ALS approval in EU; will seek re-examination","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CHMP adopted negative opinion on conditional marketing authorisation for AMX0035 (ALBRIOZA) for ALS in EU.","Company will request formal re-examination, a ~4-month process with new rapporteur and co-rapporteur.","Topline results from global Phase 3 PHOENIX study expected mid-2024.","ALS affects ~30,000 people in Europe; no new ALS innovations approved in EU in over 25 years.","AMX0035 is approved in the U.S. and with conditions in Canada based on CENTAUR trial data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299319,"accession_number":"0001193125-23-164027","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Amylyx shareholders elect two Class II directors and ratify Deloitte as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["George Mclean Milne Jr. and Paul Fonteyne elected as Class II directors; term until 2026.","Milne received 44,362,315 votes for, 9,410,140 withheld; Fonteyne 44,736,816 for, 9,035,639 withheld.","Ratification of Deloitte & Touche as independent auditor for FY 2023 passed with 57,585,098 votes for.","No other matters were submitted to or voted on at the annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299318,"accession_number":"0000950170-23-021181","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx Q1 net product revenue $71.4M; net income $1.6M vs $47.8M loss YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $71.4M from RELYVRIO/ALBRIOZA ALS sales; cost of sales $5.3M.","Net income $1.6M ($0.02/share) vs net loss $47.8M ($0.93/share) in Q1 2022.","Cash and investments $345.7M at March 31, 2023, down slightly from $346.9M at Dec 31, 2022.","Phase 3 PHOENIX ALS trial fully enrolled (664 participants); topline results expected mid-2024.","Plans to initiate global Phase 3 trial of AMX0035 in progressive supranuclear palsy in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":71428000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319477,"accession_number":"0001193125-23-075821","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2023-03-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Amylyx appoints Karen Firestone to board of directors, effective March 16, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Karen Firestone appointed as Class I director effective March 16, 2023.","Will serve on Audit Committee and Nominating and Corporate Governance Committee.","Eligible for annual cash retainer of $45,000 plus committee retainer fees.","Granted initial option for 27,403 shares; one-third vests in 1 year, balance over 2 years.","Director compensation policy amended January 20, 2023, filed as exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319476,"accession_number":"0000950170-23-007580","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx reports $22.2M full-year product revenue; net loss $198.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net product revenue $21.9M; full-year 2022 net product revenue $22.2M from RELYVRIO/ALBRIOZA sales.","Net loss for 2022 was $198.4M ($3.39 per share) vs. $87.9M in 2021; cash & short-term investments $346.9M.","Phase 3 PHOENIX trial fully enrolled (664 participants); topline data expected mid-2024.","EU MAA regulatory review ongoing; company now expects CHMP opinion mid-2023 and decision Q3 2023 at earliest.","Karen Firestone appointed to Board of Directors effective March 16; raised $230.6M net in October 2022 public offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319475,"accession_number":"0001193125-23-036988","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2023-02-14T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Amylyx expects Q4 and FY 2022 revenue to meaningfully exceed consensus on higher RELYVRIO demand","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Insurers covering ~25% of U.S. covered lives have published policies; nearly all provide broad access to RELYVRIO.","EU decision on AMX0035 marketing authorization for ALS expected first half 2023; CHMP SAG meeting this month.","Phase 3 PHOENIX trial (664 participants) completed enrollment; topline results anticipated mid-2024.","Starting Feb 19, pharmacy network data will no longer flow to third-party data vendors (closed network model).","Company provides update at SVB Securities conference; Q4 and FY 2022 financial results call in early March 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337674,"accession_number":"0001193125-22-299375","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2022-12-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Amylyx CMO Patrick Yeramian moves to part-time, salary reduced to $214K; successor search ongoing","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CMO Patrick Yeramian's working hours reduced to 20 per week as of Dec 1, 2022.","Base salary adjusted to $214,000 annually from prior rate (not disclosed).","Company expects Yeramian to transition into retirement; no definitive date set.","Full-time successor search initiated as part of management succession process.","Yeramian's reduced schedule not the result of any disagreement with the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337673,"accession_number":"0000950170-22-024448","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx reports Q3 net loss of $53.8M; FDA-approved RELYVRIO now commercially available in U.S.","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA approval of RELYVRIO for ALS on Sep 29; shipments began Oct 24.","ALBRIOZA launched in Canada Jul 29, generating $0.3M net product revenue in Q3.","Net loss $53.8M ($0.92/sh) vs $23.1M ($3.42/sh) YoY; R&D and SG&A costs rose on launch preparation.","Cash $162.6M at Sep 30, plus $230.8M net from October stock offering.","EMA decision on AMX0035 expected first half 2023; MAA under review."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":345000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337672,"accession_number":"0001193125-22-275812","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Isaac Cheng resigns from Amylyx board effective Nov 1, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Isaac Cheng, MD, resigned from the board of directors on November 1, 2022.","Resignation is not due to any disagreement with the company on operations, policies, or accounting.","Board size reduced by one; no replacement named in the filing.","Company thanked Dr. Cheng for his service and contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355040,"accession_number":"0001193125-22-254838","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2022-09-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA approves Amylyx's RELYVRIO for ALS; Phase 2 trial showed slowed physical decline","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved RELYVRIO (AMX0035) for adults with ALS based on Phase 2 CENTAUR trial in 137 participants that met primary efficacy endpoint.","RELYVRIO significantly slowed loss of physical function vs placebo; can be used as monotherapy or with existing ALS treatments.","Amylyx priced RELYVRIO below the latest FDA-approved ALS product; expects specialty pharmacies to start filling prescriptions within 4-6 weeks.","Most common adverse events (>=15% and >=5% over placebo) were diarrhea, abdominal pain, nausea, and upper respiratory tract infection.","Management to host investor conference call Sept 30 at 8:00 AM ET to discuss approval and commercial plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355039,"accession_number":"0001193125-22-218745","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx Q2 net loss $54.1M ($0.93/shr); ALBRIOZA launched in Canada; FDA PDUFA Sept 29","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $54.1M vs $21.9M in Q2 2021; R&D $24.3M, G&A $30.0M; no product revenue.","Cash & equivalents $206.7M at June 30, down from $255.2M at March 31, 2022.","ALBRIOZA (AMX0035) commercially launched in Canada on July 29, 2022.","FDA AdCom meeting Sept 7, 2022; PDUFA decision date Sept 29, 2022 for ALS NDA.","EU MAA under review; decision expected first half 2023; commercial prep underway."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355038,"accession_number":"0000950170-22-016880","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amylyx reports Q2 net loss $54.1M; ALBRIOZA launched in Canada; FDA PDUFA Sept 29","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $54.1M ($0.93/sh) vs $21.9M ($3.41/sh) in Q2 2021; cash $206.7M at quarter end.","ALBRIOZA (AMX0035) commercially launched in Canada on July 29, 2022 – first product launch.","FDA Advisory Committee meeting for ALS NDA scheduled Sept 7, 2022; PDUFA action date Sept 29, 2022.","EU MAA under review; EMA decision expected first half 2023, with launch prep underway.","R&D expense $24.3M (up from $10.9M); G&A expense $30.0M (up from $7.7M) driven by commercial readiness."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355037,"accession_number":"0001193125-22-188015","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2022-07-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA plans to reconvene advisory committee for Amylyx's ALS drug AMX0035 on Sept 7","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA to reconvene PCNSDAC on September 7, 2022 to discuss AMX0035 NDA for ALS.","Discussions will focus on additional analyses of clinical data deemed a major amendment to the NDA.","PDUFA target action date extended to September 29, 2022 from June 29, 2022 for FDA review.","Advisory committee previously met March 30, 2022; new meeting signals continued FDA scrutiny."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373117,"accession_number":"0001193125-22-172425","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2022-06-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Amylyx receives first global approval: Health Canada approves ALBRIOZA for ALS","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Health Canada approved ALBRIOZA (AMX0035) with conditions for ALS; first marketing approval worldwide.","Approval based on Phase 2 CENTAUR trial showing 2.32-point higher ALSFRS-R score vs placebo over 24 weeks.","Condition requires data from ongoing Phase 3 PHOENIX trial; topline results expected in 2024.","ALBRIOZA expected to be commercially available in Canada within six weeks.","FDA PDUFA date set for Sept 29, 2022; EMA application under review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373116,"accession_number":"0001193125-22-171014","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","form_type":"8-K","filed_at":"2022-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Amylyx shareholders elect Class I directors and ratify Deloitte as auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Justin Klee elected Class I director with 42,100,898 votes for, 1,607,476 withheld.","Isaac Cheng elected Class I director with 41,946,619 votes for, 1,761,755 withheld.","Ratification of Deloitte & Touche as independent auditor for FY2022 approved with 43,834,729 votes for, 72,090 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1576621947.657427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-06-09T23:59:59+00:00|373116"}